Regions Macau

FDA awards GSA breakthrough status for relapsed osteosarcoma treatment

The decision is backed by data from the randomised multi-centre Phase II ARTEMIS-002 trial.

By: Pharmaceutical Technology

Jan 10 2025
1
273 Views

FDA awards GSA breakthrough status for relapsed osteosarcoma treatment

GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate (ADC), GSK'227, to treat adults with relapsed or refractory … [+2396 chars]

Wynn Macau (OTCMKTS:WYNMY) & Civeo (NYSE:CVEO) Critical Survey

Kerzner CEO Explains How to Scale New Brands While Keeping One&Only and Atlantis Exclusive

FDA awards GSA breakthrough status for relapsed osteosarcoma treatment

Macau casino operator opens Thai office

UFC London Opening Odds: Jan Blachowicz Vs. Carlos Ulberg

Casino operator Melco has opened a new office in Bangkok

Opinion: 5 things Macao needs to address as part of its economic diversification

New policy to boost employment for local youth in Hengqin

Community advisor calls for more global perspective for the year-end celebrations

Xia Baolong urges Macau to achieve greater international recognition

GDP projected to grow by 7.7% in 2025 amid global uncertainties

Survey finds youth struggle to grasp Hengqin development policies

Facebook

Pinterest

Linkedin

Jan Jansen Easy Branches

Tumblr

Easy Branches

Instagram

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

FDA awards GSA breakthrough status for relapsed osteosarcoma treatment

Related